Agenus Inc. (AGEN) News
Follow Agenus Inc. (AGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Agenus 3Q 2026: Revenue $31.49M, EPS $0.02 — 10-Q Summary
Agenus’ third-quarter revenue edged higher year over year, while net income attributable to common stockholders declined. Pre-commercial BOT/BAL sales through early access programs partially offset lower non-cash royalty
EARNINGS | Nov 05, 2026, 09:38 PM UTC
M
Agenus Reports Q3 Revenue of $31.5 Million and Operating Income of $11.4 Million
Agenus reported third-quarter 2026 net income of $2.8 million and ended September with $86.9 million in cash, cash equivalents and short-term investments. The company is preparing its Phase 3 ROBBIN trial.
EQUITY | Nov 05, 2026, 01:03 PM UTC
M
Agenus Reports Third-Quarter 2026 Results and BOT+BAL Authorizations
Agenus reported third-quarter 2026 results, with first marketing authorizations for BOT+BAL. The Phase 3 ROBBIN study remains on track for first patient enrollment in Q1 2027, with strong global investigator engagement.
EQUITY | Nov 05, 2026, 12:31 PM UTC
M
Agenus Reports 100% Major Pathologic Response in dMMR Combination Cohort
In the 14-patient dMMR/MSI-H BOT+BAL cohort, all patients achieved a major pathologic response and 13 (93%) achieved a complete response. At the February 9, 2026 cutoff, no BOT+BAL patients had recurrence; 12-month event
EQUITY | Nov 02, 2026, 11:43 AM UTC
M
Agenus BOT+BAL Meets Primary Endpoint in Phase 2 Colon Cancer Trial
Agenus said its BOT+BAL treatment met the primary endpoint in a Phase 2 trial in microsatellite-stable colon cancer.
EQUITY | Nov 02, 2026, 11:43 AM UTC
M
Agenus to Release Third-Quarter 2026 Results on November 5
Agenus said it will release its third-quarter 2026 financial results before the market opens on November 5, 2026, and review recent development progress.
EQUITY | Oct 22, 2026, 08:30 PM UTC
L
Agenus to Present agenT-797 Long-Term Data at SITC 2026
AGenus said it will present BOT+BAL long-term survival data and translational research with agenT-797 in colorectal cancer at SITC 2026.
EQUITY | Oct 02, 2026, 01:02 PM UTC
L
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL),
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
Agenus announces peer-reviewed publication on BOT+BAL in MSS metastatic CRC
Agenus says a peer-reviewed publication links BOT+BAL’s durable survival in MSS metastatic colorectal cancer to its immune-priming mechanism.
EQUITY | Aug 28, 2026, 02:07 PM UTC
L
Agenus updates NEST Phase 2 publication in resectable colon cancer
Agenus says it has published updated Phase 2 NEST results for neoadjuvant BOT+BAL in resectable colon cancer, citing deep pathologic responses and no observed recurrences.
EQUITY | Aug 26, 2026, 02:05 PM UTC
L
AGEN Agenus files to sell 2.13M shares of common stock for holders
AGEN Agenus files to sell 2.13M shares of common stock for holders
EQUITY | Jul 20, 2026, 10:54 AM UTC
H
Stock Market Today: Dow Jones Futures Fall, Nasdaq 100 Gains as Trump Calls US the 'Guardian' of Hormuz Strait—Tower Semiconductor, Twin Vee
U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and S&P 500 indices fell, following Monday’s lower close. As the U.S. and Iran attacks continued for the third straight nigh
CENTRAL_BANK | Jul 14, 2026, 09:28 AM UTC
L
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
EQUITY | Jul 13, 2026, 04:19 PM UTC
L
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active L
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
EQUITY | Jul 06, 2026, 11:30 AM UTC
M
AGEN Presents Survival Data
Agenus announces three-year survival data from Phase 1b BOT+BAL study in MSS metastatic colorectal cancer to be presented at ESMO GI 2026
EQUITY | Jun 25, 2026, 11:00 AM UTC